UBS Asset Management Americas Inc. reduced its stake in shares of Reata Pharmaceuticals Inc (NASDAQ:RETA) by 1.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 183,997 shares of the company’s stock after selling 2,793 shares during the quarter. UBS Asset Management Americas Inc.’s holdings in Reata Pharmaceuticals were worth $5,211,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Bank of New York Mellon Corp grew its position in Reata Pharmaceuticals by 31.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 44,703 shares of the company’s stock worth $1,391,000 after purchasing an additional 10,744 shares during the period. Schwab Charles Investment Management Inc. grew its position in Reata Pharmaceuticals by 83.2% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 49,828 shares of the company’s stock worth $1,550,000 after purchasing an additional 22,628 shares during the period. TIAA CREF Investment Management LLC grew its position in Reata Pharmaceuticals by 39.6% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 23,041 shares of the company’s stock worth $729,000 after purchasing an additional 6,541 shares during the period. Northern Trust Corp grew its position in Reata Pharmaceuticals by 39.3% during the 2nd quarter. Northern Trust Corp now owns 98,046 shares of the company’s stock worth $3,102,000 after purchasing an additional 27,669 shares during the period. Finally, Candriam Luxembourg S.C.A. acquired a new stake in shares of Reata Pharmaceuticals during the 3rd quarter valued at about $1,866,000. 49.33% of the stock is currently owned by institutional investors.
Shares of Reata Pharmaceuticals Inc (NASDAQ:RETA) opened at $22.15 on Monday. Reata Pharmaceuticals Inc has a 12-month low of $19.48 and a 12-month high of $40.88. The company has a debt-to-equity ratio of -0.13, a quick ratio of 2.80 and a current ratio of 2.80.
In other news, major shareholder James W. Traweek, Jr. acquired 121,725 shares of the stock in a transaction that occurred on Wednesday, December 13th. The shares were bought at an average cost of $24.88 per share, for a total transaction of $3,028,518.00. Following the acquisition, the insider now owns 35 shares in the company, valued at approximately $870.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Cpmg Inc acquired 200,000 shares of the stock in a transaction that occurred on Thursday, December 14th. The stock was purchased at an average price of $24.79 per share, for a total transaction of $4,958,000.00. Following the completion of the acquisition, the director now owns 113 shares in the company, valued at approximately $2,801.27. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 409,925 shares of company stock worth $10,359,964. 44.00% of the stock is currently owned by insiders.
A number of research firms have recently commented on RETA. Cowen restated a “buy” rating on shares of Reata Pharmaceuticals in a research report on Thursday, December 14th. BidaskClub cut Reata Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, February 23rd. Finally, Zacks Investment Research cut Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, January 24th. Three analysts have rated the stock with a sell rating and eight have assigned a buy rating to the company. Reata Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $54.71.
ILLEGAL ACTIVITY NOTICE: “UBS Asset Management Americas Inc. Has $5.21 Million Holdings in Reata Pharmaceuticals Inc (RETA)” was first posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.themarketsdaily.com/2018/03/12/ubs-asset-management-americas-inc-has-5-21-million-holdings-in-reata-pharmaceuticals-inc-reta.html.
Reata Pharmaceuticals Profile
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
Want to see what other hedge funds are holding RETA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Reata Pharmaceuticals Inc (NASDAQ:RETA).
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.